Feasibility of peripheral blood stem cell collection from sickle cell trait donors with an intensified G‐CSF regimen

URN to cite this document:: urn:nbn:de:bvb:355-epub-546369
DOI to cite this document:: 10.5283/epub.54636

Mohrez, Morad ; Troeger, Anja ; Kleinschmidt, Katharina ; Hanafee Alali, Tarek ; Jakob, Marcus ; Brosig, Andreas Michael

; Hähnel, Viola

; Kietz, Silke ; Offner, Robert

; Burkhardt, Ralph

; Corbacioglu, Selim

; Ahrens, Norbert

; Foell, Juergen

License: Creative Commons Attribution Non-commercial 4.0
PDF - Published Version
Early view
(1MB)

Date of publication of this fulltext: 29 Aug 2023 05:49

Alternative links to fulltext:DOI Publisher

This publication is part of the DEAL contract with Wiley.

Details

Preview: Early view

Indexed in

Export bibliographical data

Abstract

Objectives: Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for SCD and bone marrow from an HLA-matched sibling is currently the standard of care. Haploidentical HSCT from a family donor with a TCR alpha beta/CD19 depleted graft (T-haplo) is an increasingly successful alternative, which requires the generation of G-CSF stimulated peripheral stem cell ...